ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Biohaven Completes Enrollment in Phase 3 Migraine Prevention Trial americanpharmaceuticalreview
August 09, 2019Biohaven has reported completion of enrollment in its pivotal Phase 3 preventive treatment of migraine trial with rimegepant, its lead oral calcitonin gene-related peptide (CGRP) receptor antagonist product candidate.
Pharma Sources Insight January 2025
